A report of three cases of untreated Graves’ disease associated with pancytopenia in Malaysia

Authors

  • Fan Kee Hoo Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia(UPM), Serdang, Selangor D.E., Malaysia

Keywords:

Graves’ disease, hyperthyroidism, thyrotoxicosis, pancytopenia

Abstract

Generally, clinical presentations of Graves’ disease range from asymptomatic disease to overt symptomatic hyperthyroidism with heat intolerance, tremor, palpitation, weight loss, and increased appetite. However, atypical presentation of Graves’ disease with hematological system involvement, notably pancytopenia, is distinctly uncommon. Hereby, we present and discuss a series of three untreated cases of Graves’ disease clinically presented with pancytopenia and the hematological abnormalities that responded well to anti-thyroid treatment. With resolution of the thyrotoxic state, the hematological parameters improved simultaneously. Thus, it is crucial that anti-thyroid treatment be considered in patients with Graves’ disease and pancytopenia after a thorough hematological evaluation.

References

Ellis H.Robert Graves: 1796-1852. Br J Hosp Med (Lond). 2006 Jun;67(6):313-313. PubMedPMID:16821741. Epub: 2013/27/9. eng. DOI:http://dx.doi.org/10.12968/hmed.2006.67.6.21291.2.Jacobson EM, Tomer Y. The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet andits contribution to thyroid autoimmunity: back to the future. J Autoimmun.;28(2-3):85–98. PubMedPMID:17369021. PMCID: PMC2043086. DOI:http://dx.doi.org/10.1016/j.jaut.2007.02.006.3.Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am. 2006Dec;35(4):663–86, vii. PubMedPMID: 17127140. DOI:http://dx.doi.org/10.1016/j.ecl.2006.09.008.4.Hambsch K, Herrmann F, Fischer H, Langpeter D, Mäller P, Sorger D. Changes in the blood picture inhyperthyroidism. Z Gesamte Inn Med. 1989;44(10):300–6. PubMedPMID: 2503948.5.Lima CSP, Zantut Wittmann DE, Castro V, Tambascia MA, Lorand-Metze I, Saad STO, et al.Pancytopenia in untreated patients with Graves’ disease. Thyroid. April 2006 ;16(4):403–9.PubMedPMID:16646688. DOI:http://doi:10.1089/thy.2006.16.403.6.Hegazi M, Kumar R, Bitar Z, Ibrahim E. Pancytopenia related to Graves’ disease. Ann SaudiMed.2008;28(1):48–9.PubMedPMID: 18299644. Epub: 2010/5/6. eng. DOI:http://dx.doi.org/10.4103/0256-4947.51769.7.Low B, Kok VC. Hyperthyroidism with Pancytopenia : A Case Report and Literature Review. Formos JEndocrin Metab. 2008;1(1):23–8.

Soeki T, Tamura Y, Kondo N, Shinohara H, Tanaka H, Bando K, et al. A case of thyrotoxicosis withpancytopenia. Endocr J. 2001 Jun ;48(3):385–9. PubMedPMID: 11523911. Epub: 2006/11/25. eng. DOI:http://dx.doi.org/10.1507/endocrj.48.385.9.Weinzierl EP, Arber D a. The differential diagnosis and bone marrow evaluation of new-onsetpancytopenia. Am J Clin Pathol. 2013 Jan;139(1):9–29. PubMedPMID: 23270895. DOI:http://dx.doi.org/10.1309/ajcp50aeeygrewuz.10.Watanabe N, Narimatsu H, Noh JY, Yamaguchi T, Kobayashi K, Kami M, et al. Antithyroid drug-inducedhematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385patients with Graves’ disease. J Clin Endocrinol Metab. 2012 Jan;97(1):E49–53. PubMedPMID:22049174.Epub: 2011/11/02. eng. DOI:http://dx.doi.org/10.1210/jc.2011-22

Downloads

Published

2022-03-08